ASKA Pharmaceutical
As of the edition of 20 October 2026, ASKA Pharmaceutical runs 11 drugs, 11 of them marketed; it is on route A at 0 targets and on route B at 7 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 11 |
| Total | 11 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Progesterone | none listed | 3 |
| Estradiol | Ends 2032 (patent) | 6 |
| Rifaximin | Ends 2027 (patent) | 0 |
| Fenofibrate | none listed | 3 |
| Levothyroxine | none listed | 6 |
| Drospirenone | none listed | 5 |
| Relugolix | Ends 2033 (patent) | 3 |
| Candesartan cilexetil | none listed | 2 |
| Norethindrone acetate | none listed | 3 |
| Norethindrone | none listed | 3 |
| Roxatidine | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 7 targets.
All 7 rows on route A or B
In the product7 company-target rows on route A or B; 4 are not shown here, and no score is.
See all 7 targets where ASKA Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Pregnancy and women's health: 1 trials led
- Urinary and reproductive: 1 trials led